Adult Dosing

Tinea pedis

• Apply bid x 4 weeks to the affected areas between the toes and the surrounding healthy skin
• Re-evaluate diagnosis if no clinical improvement in 2 wks

Pediatric Dosing

Tinea pedis

• >12 yrs: Apply bid x 4 weeks
• Safety and effectiveness in pediatric <12 yrs have not been established

[Outline]

• Adult Dosing
• Pediatric Dosing

• Interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum

• Hypersensitivity to any of the ingredients of the product
• Hypersensitivity to imidazoles

• N/A

Renal Dose Adjustment

• Renal impairment: No dose adjustments

Hepatic Dose Adjustment

• Hepatic impairment: No dose adjustments

See Supplemental Patient Information

• Sertaconazole is not indicated for ophthalmic, oral or intravaginal use
• Avoid contact with the eyes, nose, mouth and other mucous membranes
• Discontinue the drug if any irritation or sensitivity develops and provide appropriate therapy
• Confirm the diagnosis of the disease either by direct microscopic examination of a mounting of infected tissue in a solution of potassium hydroxide or by culture on an appropriate medium

Caution: use cautiously in

• Lactation and pregnancy

Supplemental Patient Information

• Avoid contact with eyes, nose, mouth and other mucous membranes
• Avoid the use of occlusive dressings

Pregnancy Category:C

Breastfeeding: Safety unknown. As many drugs are excreted in the breast milk, manufacturer advises caution.

• DERM: Dermatitis, rash, erythema, pruritus, vesiculation, desquamation, hyperpigmentation, dry skin, application site reaction, skin burning, skin tenderness

• Antifungal; thought to be responsible for inhibition of ergosterol synthesis, a component of fungal cell membrane, resulting in cytoplasmic leakage and fungal cell death
• Minimal systemic absorption
• Metabolism: Unknown
• Excretion: Unknown
• Half-life: Unknown

US Trade Name(s)

• Ertaczo

US Availability

Ertaczo

• CRE: 2%

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

[Outline]

Antimicrobials

Dermatologic Topical Agents

Antifungals

Infectious Disease

Dermatologic Topical Agents

Antifungals

Dermatologic

Dermatologic Topical Agents

Antifungals

Pricing data from www.DrugStore.com in U.S.A.

• Ertaczo 2 % CREA [Tube] (VALEANT)
  30 % = $126.59
  90 % = $342.87

Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.